Rakovina Therapeutics Inc (TSX-V:RKV) announced it is increasing its previously declared private placement from $2.0 million to $2.3 million in response to heightened interest from potential investors.
The terms of the private placement remain unchanged, and the company now anticipates closing the placement on or around July 22, 2024.
Rakovina Therapeutics has established a robust pipeline of novel DNA-damage response inhibitors with the aim of advancing one or more drug candidates into human clinical trials.
The company is focused on obtaining marketing approval for new cancer therapeutics from regulatory bodies such as Health Canada, the United States Food and Drug Administration, and similar international agencies.